Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
| 대상 질환 | Major Depressive Disorder, Depression |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Levomecor Inc. |
| 상태 | 조기 종료 |
| 참여자 수 | 27 명 |
| 중재(약물) | REL-1017 |
| 시작일 | 2023년 8월 17일 |
| 완료일 | 2024년 12월 19일 |
| 결과 공개일 | 2026년 7월 10일 |
요약
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
| REL-1017 | -16.8 ± 7.62 Scores on a scale (MADRS10) |
|---|---|
| Placebo | -13.4 ± 9.55 Scores on a scale (MADRS10) |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital